Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
FLYNN TIMOTHY PATRICK reported acquisition or exercise transactions in this Form 4 filing.
UnitedHealth Group director Timothy Patrick Flynn received a grant of 350 shares of Common Stock-equivalent deferred stock units on April 1 as regular quarterly compensation for Board service. These deferred stock units are immediately vested but must be retained until he completes his service on the Board.
Following this grant, Flynn directly holds 10,589 shares of UnitedHealth Group common stock. In addition, an indirect holding entry reflects 6,033 shares held by a trust, indicating a separate ownership structure for part of his overall position.
UnitedHealth Group Inc ownership disclosure: The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting that it beneficially owns 0 shares of Common Stock, representing 0%. The filing states this result follows an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 (January 12, 1998), and that certain Vanguard subsidiaries now report holdings separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
UNITEDHEALTH GROUP INC director Valerie Montgomery Rice received 53 shares of Common Stock as a grant. The Form 4 shows this as a compensation-related acquisition, with no purchase price. The footnote explains these are dividend equivalents on vested deferred stock units, which are immediately vested and follow the same terms as the underlying units. After this grant, her directly held Common Stock totals 7,272 shares.
UNITEDHEALTH GROUP INC Chief Financial Officer Wayne S. DeVeydt reported an automatic stock-based award rather than a market trade. He acquired 149.989 shares of common stock at a stated price of $0.0000 per share, increasing his direct holdings to 19,666.93 shares.
According to the footnote, these shares represent dividend equivalents paid on outstanding restricted stock units. The dividend equivalents are subject to the same vesting terms as the underlying restricted stock units and will be forfeited if those units do not vest, making this a routine compensation-related accrual rather than an open-market purchase or sale.
UNITEDHEALTH GROUP INC Chief Accounting Officer Dennis Andrew Stankiewicz reported an acquisition of common stock tied to existing equity awards. On March 17, 2026, he received 68.058 shares of common stock at no cost as dividend equivalents on outstanding restricted stock units, which are subject to the same vesting conditions and are forfeited if the underlying units do not vest. Following this award, his directly held common stock position increased to 10,205.939 shares, indicating a routine compensation-related update rather than an open-market trade.
UnitedHealth Group director Paul R. Garcia received an equity-based award linked to existing deferred stock units. On March 17, 2026, he acquired 16 shares of common stock at $0.00 per share, described as dividend equivalents paid on vested deferred stock units that are immediately vested and subject to the same terms as the underlying units.
Following this grant, Garcia directly holds 3,330 shares of UnitedHealth Group common stock. He also has indirect holdings reported through a revocable trust and additional trusts, reflecting shares held in estate-planning vehicles rather than through open‑market transactions.
UNITEDHEALTH GROUP INC director John H. Noseworthy received 52 shares of common stock as a grant tied to dividend equivalents on vested deferred stock units. The shares were acquired at no cost, are immediately vested, and follow the same terms as the underlying deferred stock units. After this award, he directly holds 7,049 shares of common stock.
UNITEDHEALTH GROUP INC executive Christopher R. Zaetta received additional common stock linked to existing equity awards. On March 17, 2026, he acquired 89.629 shares of Common Stock at a stated price of $0.00 per share, reported as a grant or award acquisition.
The footnote explains this represents dividend equivalents paid on outstanding restricted stock units. These dividend equivalents follow the same vesting terms as the underlying restricted stock units and will be forfeited if those units do not vest. After this transaction, Zaetta directly holds 16,716.169 shares of Common Stock.
UNITEDHEALTH GROUP INC executive Timothy John Noel, Chief Executive Officer of UnitedHealthcare, received an acquisition of 102.329 shares of common stock as of March 17, 2026. These shares represent dividend equivalents on outstanding restricted stock units and are granted at no cash cost to him.
After this award, his directly held common stock position reported in this filing increased to 17,574.653 shares. The dividend equivalents are subject to the same vesting conditions as the underlying restricted stock units and will be forfeited if those units do not vest, making this a routine, compensation-related equity accrual rather than an open‑market purchase.
UNITEDHEALTH GROUP INC director Frederick William McNabb III reported an automatic share-based compensation event. He acquired 64 shares of common stock on March 17, 2026 with a reported price of $0.0000 per share, described as dividend equivalents on vested deferred stock units. These dividend equivalents are immediately vested and follow the same terms as the underlying deferred stock units. After this credit, his directly held common stock position increased to 14,774 shares, reflecting a small, routine adjustment rather than an open-market purchase.